Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 465 entries
View as:

The Safety and Effectiveness of PROCRIT (Epoetin Alfa) in Patients Undergoing Elective Major Abdominal and/or Pelvic Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00350519 Org: User:
Start: 08/31/06 End: 02/29/08 Due: 02/28/09

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT00590577 Org: User:
Start: 03/31/07 End: 03/31/08 Due: 03/31/09

A Study to Evaluate the Effectiveness and Safety of Multiple Doses of Tapentadol(CG5503) in Patients Awaiting Joint Replacement Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00361582 Org: User:
Start: 10/31/06 End: 08/31/07 Due: 08/31/08

A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections

Phase: N/A Priority: Normal
NCT ID: NCT00258089 Org: User:
Start: 06/30/93 End: 01/31/95 Due: 01/31/96

Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia

Phase: N/A Priority: Normal
NCT ID: NCT00085748 Org: User:
Start: 08/31/04 End: 05/31/05 Due: 05/31/06

A Study of the Effectiveness and Safety of Dapoxetine in the Treatment of Men With Premature Ejaculation

Phase: N/A Priority: Normal
NCT ID: NCT00210704 Org: User:
Start: 03/31/05 End: 06/30/06 Due: 06/30/07

A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00035802 Org: User:
Start: 01/31/02 End: 04/30/02 Due: 04/30/03

A Safety and Pharmacokinetic Study of ER OROS Paliperidone in Pediatric Patients With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00796081 Org: User:
Start: 01/31/06 End: 08/31/06 Due: 08/31/07

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-38431055 in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00910923 Org: User:
Start: 11/30/08 End: 04/30/09 Due: 04/30/10

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Phase: N/A Priority: Normal
NCT ID: NCT00449176 Org: User:
Start: 02/28/07 End: 05/31/08 Due: 05/31/09

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase: N/A Priority: Normal
NCT ID: NCT00228995 Org: User:
Start: 06/30/04 End: 09/30/05 Due: 09/30/06

A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT01949610 Org: User:
Start: 01/31/10 End: 03/31/10 Due: 03/31/11

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00091442 Org: User:
Start: 09/30/04 End: 12/31/08 Due: 12/31/09

A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders

Phase: N/A Priority: Normal
NCT ID: NCT00236444 Org: User:
Start: 12/31/01 End: 09/30/03 Due: 09/30/04

A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.

Phase: N/A Priority: Normal
NCT ID: NCT00341055 Org: User:
Start: 06/30/03 End: 05/31/04 Due: 05/31/05

A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01286103 Org: User:
Start: 01/31/11 End: 05/31/11 Due: 05/31/12

A Pharmacodynamics, Pharmacokinetics, and Safety Study of Hydrochlorothiazide and Canagliflozin in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01294631 Org: User:
Start: 03/31/11 End: 07/31/11 Due: 07/31/12

Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00579501 Org: User:
Start: 04/30/07 End: 01/31/10 Due: 01/31/11

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01518712 Org: User:
Start: 09/30/11 End: 11/30/11 Due: 11/30/12

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Phase: N/A Priority: Normal
NCT ID: NCT00676299 Org: User:
Start: 08/31/06 End: 07/31/08 Due: 07/31/09

A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive

Phase: N/A Priority: Normal
NCT ID: NCT00747695 Org: User:
Start: 03/31/08 End: 09/30/09 Due: 09/30/10

Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older

Phase: N/A Priority: Normal
NCT ID: NCT00048503 Org: User:
Start: 06/30/02 End: 11/30/05 Due: 11/30/06

An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury

Phase: N/A Priority: Normal
NCT ID: NCT01814982 Org: User:
Start: 08/31/07 End: 08/31/08 Due: 08/31/09

Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00061802 Org: User:
Start: 06/30/03 End: 02/29/04 Due: 02/28/05

A Pharmacokinetics and Pharmacodynamics Study Under Fasting and Fed Conditions With Paliperidone Extended-release and Immediate-release Formulations

Phase: N/A Priority: Normal
NCT ID: NCT00796471 Org: User:
Start: 06/30/03 End: 08/31/03 Due: 08/31/04